Valeant Hit With Shareholder Suit Over $3B Biovail Deal
Valeant Pharmaceuticals International Inc. and its directors have been hit with a shareholder class action seeking to block the company's $3.2 billion deal to merge with Biovail Corp....To view the full article, register now.
Already a subscriber? Click here to view full article